Research Forecasts on Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016
Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Herpes Simplex Virus (HSV) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Herpes Simplex Virus (HSV) Infections, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Simplex Virus (HSV) Infections and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
To access full report with TOC, please visit Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016.
Scope
- The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Virus (HSV) Infections
- The report reviews pipeline therapeutics for Herpes Simplex Virus (HSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Simplex Virus (HSV) Infections
- The report reviews pipeline therapeutics for Herpes Simplex Virus (HSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Simplex Virus (HSV) Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Virus (HSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Simplex Virus (HSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Virus (HSV) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Simplex Virus (HSV) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamis Pharmaceuticals Corporation Admedus Ltd AiCuris GmbH & Co. KG Almirall, S.A. Astellas Pharma Inc. Beech Tree Labs, Inc. Beijing Minhai Biotechnology Co., Ltd BioApex, s.r.o. CEL-SCI Corporation Editas Medicine, Inc. Epiphany Biosciences, Inc. Foamix Pharmaceuticals Ltd. Genocea Biosciences, Inc. GenVec, Inc. Immune Design Corp. Immunovaccine, Inc. JN-International Medical Corporation Microbiotix, Inc. Mymetics Corporation NanoBio Corporation NanoViricides, Inc. Onxeo SA PaxVax, Inc. Profectus BioSciences, Inc. ReceptoPharm, Inc. Redbiotec AG Sanofi Sanofi Pasteur SA Savoy Pharmaceuticals, Inc. Shulov Innovative Science Ltd. Spider Biotech Starpharma Holdings Limited TGV-Laboratories Tomegavax, Inc. United BioPharma, Inc. Vaccibody AS Vaxart, Inc. Vical Incorporated Vironova AB ViroStatics srl
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 05:53
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home